Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Cannabist in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $0.27.
Current Consensus is
N/A
The current consensus among 0 investment analysts is to n/a stock in Cannabist. This N/A consensus rating has held steady for over two years.
The Cannabist Company Holdings Inc. engages in the cultivation, manufacture, and provision of cannabis products and related services in the United States and internationally. The company offers spanning flower, edibles, oils, and tablets under the Seed & Strain, Triple Seven, Hedy, gLeaf, Classix, Press, and Amber brand names. It holds licenses in 17 jurisdictions in the United States. The company was formerly known as Columbia Care Inc. and changed its name to The Cannabist Company Holdings Inc. in September 2023. The company was founded in 2012 and is headquartered in New York, New York.
Read More